Bial Foundation for LIMMIT Laboratory instalation
Bial Foundation for research Project
"Intention and Brain to Brain Communication with Non Invasive Techniques"
PI: Anabela Ventura
Induced near-death-experiences in healthy volunteers: Phenomenology, psychophysiology and after effects
PI: Simões, M.
Doctoral Research Project: Sofia Machado Ferreira
Ana Paula Farinha Resende (External collaboration)
MolecularCog(G) studies cognition with top-down molecular biology techniques in a omics perspective. The purpose is to address the premise, as defined in enactive approach, that cognition itself has a molecular coupling: the neuroendocrine-immune interface. http://salivatec.weebly.com/molecularcog-g.html
European Union's Horizon 2020 CORBEL, research and innovation programme grant agreement No. 65424" - CORBEL PID2277 Molecular insight into Autism Spectrum Disorder (ASD).
Description:
Current screening tools for Autism Spectrum Disorder (ASD) are based on social behavior, and other clinical observations, which have limitations in terms of patient stratification, diagnosis sensitivity and assessment of treatment outcomes, especially on early screening (12 months). On the other hand, interventions for ASD have been shown in many studies to be most effective when initiated early, therefore, early screening of ASD is imperative. Biomarkers for ASD could potentially ai d in early ASD diagnosis, detection at any age, and may help to elucidate and stratify ASD subtypes, and more importantly to characterize the subtypes which are more prone to a specific clinical intervention.
Salivatec, UCP. PI: Maria José Correia, Marlene Barros, Nuno Rosa Jorge Martins
European Union's Horizon 2020 CORBEL, research and innovation programme grant agreement No. 65424" - CORBEL PID2277 Molecular insight into Autism Spectrum Disorder (ASD).
Description:
Current screening tools for Autism Spectrum Disorder (ASD) are based on social behavior, and other clinical observations, which have limitations in terms of patient stratification, diagnosis sensitivity and assessment of treatment outcomes, especially on early screening (12 months). On the other hand, interventions for ASD have been shown in many studies to be most effective when initiated early, therefore, early screening of ASD is imperative. Biomarkers for ASD could potentially ai d in early ASD diagnosis, detection at any age, and may help to elucidate and stratify ASD subtypes, and more importantly to characterize the subtypes which are more prone to a specific clinical intervention.
Salivatec, UCP. PI: Maria José Correia, Marlene Barros, Nuno Rosa Jorge Martins
